1st November 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Akums collaborates with Microcore Research to manufacture NESM supplements

The leading contract manufacturing pharma company in India has tied-up with Microcore Research, which is the only manufacturer of Natural Eggshell Membrane (NESM) to leverage the NSEM to develop dietary supplements for maintaining healthy joint and connective tissues.

Jubilant Generics Roorkee unit determined as official action indicated

Jubilant Generics Limited (JGL) has received a communication from the US FDA which concluded that pursuant to its July-Aug 2022 audit of JGL’s Solid Dosage Manufacturing facility at Roorkee, it has determined inspection classification of the facility as “official action indicated” .

Sun Pharma's consolidated net profit may dip 4% over high R&D costs

Sun Pharmaceuticals is likely to report muted operating performance and earnings with a 4% decline in the on-year consolidated net profit for the quarter that ended in September 2022. On the other hand, the company’s consolidated revenue is expected to rise 13.2% on a year-onyear basis.

Gland Pharma shares falls 24% in just 3 sessions.

Shares of Gland Pharma Limited plunged another over 7% to dip even lower to ₹1,738 apiece on the BSE (Bombay Stock Exchange) in Monday’s deals. The company’s stock has been under constraint for the past few days and has declined more than 24% in just last three sessions.

Maiden Pharma's 19 batches of albendazole tablets fails quality tests

As many as 19 batches of antiparasitic medication tablets manufactured by the Sonepat, Haryana facility of Maiden Pharmaceuticals have failed a quality test. Haryana Medical Services Corporation Ltd (HMSCL) obtained these tablets for government hospitals and dispensaries.

Glenmark Pharmaceuticals launches Fingolimod Capsules in US

Glenmark Pharmaceuticals Inc. USA, announced the launch of Fingolimod Capsules (0.5 mg), the generic version of Gilenya Capsules (0.5 mg) manufactured by Novartis Pharmaceuticals.The drug is approved to treat relapse Multiple Sclerosis (MS) in adults and children over the age of ten.

First Adderall, now Amoxicillin runs out of stock amongst increased demand

Oral solution of the common antibiotic Amoxicillin which is usually given to children to treat bacterial infections are running short in the US market as respiratory infections in children rose over the holiday season. The agency said on its online drug shortage database that supplies from multiple drugmakers are “on allocation” amid a period of heightened demand.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?